Innate Lymphoid Cells in Critical Illness: Mechanisms, Clinical Impact, and Emerging Therapeutic Perspectives

Abstract

Innate lymphoid cells (ILCs) have emerged as crucial mediators in the immune landscape of critical illness, orchestrating early immune responses and influencing outcomes in conditions such as sepsis, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome (MODS). This review synthesizes current evidence regarding the epidemiology, functional roles, and clinical relevance of ILCs in critical illness. It further addresses diagnostic approaches, therapeutic implications, and recent advances, providing a comprehensive resource for healthcare professionals managing critically ill patients.

Introduction

Critical illness encompasses a spectrum of life-threatening conditions, including sepsis, severe trauma, and acute organ failures, which are characterized by profound immune dysregulation. Over the past decade, research has highlighted the pivotal role of innate lymphoid cells lymphocytes lacking antigen-specific receptors but possessing potent cytokine-secreting capabilities in shaping the early immune milieu during critical illness. ILCs, particularly the three main subtypes (ILC1, ILC2, and ILC3), are now recognized as key players not only in barrier defense but also in modulating inflammation, tissue repair, and systemic immune responses in the critically ill.

Epidemiology / Disease Burden

The morbidity and mortality associated with critical illness remain high worldwide, with sepsis and ARDS among the leading causes of intensive care unit (ICU) admissions. Recent studies estimate that up to 30-45% of ICU patients exhibit significant alterations in ILC populations, with changes in ILC frequency and function correlating with disease severity and outcomes. The burden of ILC-mediated immune dysregulation is particularly evident in immunocompromised and elderly populations, where shifts in ILC subsets may predispose to secondary infections, persistent inflammation, and poor recovery.

Pathophysiology

ILCs are divided into three main groups based on transcription factor expression and cytokine profiles: ILC1 (T-bet+; IFN-γ producers), ILC2 (GATA-3+; IL-5/IL-13 producers), and ILC3 (RORγt+; IL-17/IL-22 producers). In critical illness, these cells are rapidly recruited to sites of tissue injury and inflammation. ILC1s contribute to early antimicrobial responses but may exacerbate tissue damage if dysregulated. ILC2s are implicated in tissue repair and resolution of inflammation, yet excessive activation can drive pathological fibrosis and airway hyperreactivity. ILC3s help maintain mucosal barrier integrity but may fuel systemic inflammation in the context of gut barrier breakdown, as seen in septic shock. The dynamic interplay between ILCs and other immune cells such as dendritic cells, neutrophils, and regulatory T cells modulates both protective and deleterious responses in critical illness.

Risk Factors

Several factors predispose critically ill patients to ILC dysregulation, including advanced age, underlying immunosuppression (e.g., chemotherapy, hematologic malignancies), chronic comorbidities (e.g., diabetes, chronic lung disease), and pre-existing barrier dysfunction (e.g., gut or pulmonary epithelium). Certain genetic polymorphisms affecting cytokine receptors or transcription factors may further influence ILC responses. Iatrogenic factors, such as prolonged corticosteroid therapy and antibiotic-induced microbiome alterations, can also disrupt ILC homeostasis, compounding the risk of immune dysfunction.

Clinical Features

While ILCs are not directly detected in routine clinical practice, their activation and dysregulation are reflected in the clinical manifestations of critical illness. Exaggerated cytokine release, persistent fever, refractory shock, and secondary infections may all be linked to imbalance in ILC function. For example, increased ILC2 activity has been associated with persistent pulmonary inflammation in ARDS, whereas ILC3-driven IL-17 production may underlie sepsis-induced gut barrier failure and bacteremia. Recognition of these patterns can aid clinicians in identifying patients at risk for immune-mediated complications.

Diagnosis

Assessment of ILCs currently relies on advanced immunophenotyping techniques, such as flow cytometry and single-cell RNA sequencing, utilizing markers including CD127, CRTH2, NKp44, and lineage exclusion panels. Recent advances in the detection of ILC-derived cytokines (e.g., IL-22, IL-13) in plasma may provide surrogate biomarkers for clinical studies, though these are not yet standard in ICU settings. Research protocols increasingly incorporate ILC profiling to stratify patients and predict outcomes, paving the way for future diagnostic integration.

Treatment & Management

Management of ILC-mediated immune responses in critical illness remains largely supportive, focusing on source control, organ support, and mitigation of secondary insults. However, emerging strategies targeting specific cytokine pathways (e.g., anti-IL-17, anti-IL-13 antibodies) are under investigation for their potential to modulate ILC activity and restore immune balance. Immunonutrition, microbiome modulation, and judicious use of immunosuppressives may also impact ILC function and are areas of active clinical exploration.

Recent Advances / Emerging Therapies

Recent translational studies have highlighted several promising therapeutic avenues, including small molecule inhibitors of ILC-related cytokines and adoptive transfer of regulatory ILC subsets. Early-phase clinical trials are exploring the safety and efficacy of monoclonal antibodies targeting ILC-driven pathways in ARDS and sepsis. Additionally, interventions aimed at restoring mucosal barrier function and microbiome diversity are being evaluated for their indirect effects on ILC homeostasis. The integration of high-dimensional immune profiling and machine learning is expected to accelerate discovery and personalize therapy in the near future.

Guideline Recommendations

Current international guidelines for the management of sepsis, ARDS, and MODS do not yet include specific recommendations for the assessment or modulation of ILCs, largely due to the nascent stage of clinical evidence. However, experts advocate for inclusion of immune profiling including ILC analysis in clinical trials and cohort studies to better define patient subgroups and therapeutic windows. Ongoing research is likely to inform future updates and drive the translation of ILC-targeted interventions into clinical practice.

Conclusion

Innate lymphoid cells represent a frontier in the understanding of immune regulation during critical illness. Their unique roles in barrier defense, inflammation, and tissue repair offer both challenges and opportunities for novel therapeutic strategies. As evidence continues to evolve, integration of ILC profiling and targeted interventions may enhance precision medicine approaches for critically ill patients, ultimately improving outcomes in this vulnerable population.